Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome.
Alemtuzumab is an antibody binding to CD52, an antigen expressed on lymphocytes. This immunotherapy has been tested as potential therapy in haematological malignancies. We report adenoviral and enteroviral infections and an EBV positive B-cell lymphoma after alemtuzumab therapy. These fatal opportunistic complications have been rarely, if ever, reported before.
Roch
Nathalie
N
Department of Infectious Diseases, University Hospital, Grenoble, France. NRoch@chu-grenoble.fr
Salameire
Dimitri
D
Gressin
Remy
R
Morand
Patrice
P
Epaulard
Olivier
O
Pavese
Patricia
P
Brion
Jean-Paul
JP
Stahl
Jean-Paul
JP
D000258:Adenovirus Infections, Human / Q000821:virology; D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004769:Enterovirus Infections / Q000821:virology; D020031:Epstein-Barr Virus Infections / Q000821:virology; D017809:Fatal Outcome; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006801:Humans; D016393:Lymphoma, B-Cell / Q000821:virology*; D008297:Male; D009894:Opportunistic Infections / Q000821:virology*; D012751:Sezary Syndrome / Q000276:immunology / Q000628:therapy*; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab